ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
A Protein Corona-Based Diagnostic Tool for Eroded Atherosclerotic Plaques.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Superficial plaque erosion, distinct from plaque rupture, represents a cause of residual thrombotic complications in atherosclerosis. Being able to detect plaque erosion, a mechanism that now accounts for up to 30% of acute coronary syndromes, can lead to targeted therapies, and perhaps avoid the need for urgent invasive interventions required for plaque rupture cases, thus greatly affecting clinical management. Nanoparticles (NPs) exposed to biological fluids acquire a layer of proteins on their surface, the protein corona (PC). Variations in the composition of the plasma proteome occurring in pathological conditions directly influence the composition of the PC. An NP-based diagnostic approach is presented exploiting the proteomic changes at the nano-bio interface for superficial plaque erosion detection. To this aim, an in vivo experimental murine procedure is used that recapitulates features of the pathophysiological conditions of superficial erosion. Two types of metal-organicframework (MOF) NPs for PC generation are employed: zirconium and iron (III) MOF (ZrMOF and FeMOF). It is demonstrated that Zr-MOF NPs act as plasma protein concentrators allowing the identification of a higher number of proteins, compared to unfractionated analysis of plasma. Nonetheless, It is identified thirteen plasma proteins exclusive to the superficial erosion group that might serve as signature proteins to discriminate the pathological condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.